PE20130310A1 - Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos - Google Patents

Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos

Info

Publication number
PE20130310A1
PE20130310A1 PE2012002183A PE2012002183A PE20130310A1 PE 20130310 A1 PE20130310 A1 PE 20130310A1 PE 2012002183 A PE2012002183 A PE 2012002183A PE 2012002183 A PE2012002183 A PE 2012002183A PE 20130310 A1 PE20130310 A1 PE 20130310A1
Authority
PE
Peru
Prior art keywords
clostridium difficile
treatment
antibiotic therapy
patients under
difficile infections
Prior art date
Application number
PE2012002183A
Other languages
English (en)
Inventor
Youe-Kong Shue
Sherwood Gorbach
Pamela Sears
Original Assignee
Optimer Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44992319&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130310(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Optimer Pharmaceuticals Inc filed Critical Optimer Pharmaceuticals Inc
Publication of PE20130310A1 publication Critical patent/PE20130310A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE REFIERE A UN METODO PARA TRATAR UNA INFECCION DE CLOSTRIDIUM DIFFICILE EN UN MAMIFERO QUE ESTA SIENDO SOMETIDO SIMULTANEAMENTE A UNA TERAPIA CON ANTIBIOTICOS SELECCIONADOS DE CARBACEFEMS, CARBAPENEMS, SULFONAMIDAS, ENTRE OTROS; PARA COMBATIR UNA INFECCION TAL COMO GONORREA, MALARIA, NEUMONIA, FARINGITIS, ENTRE OTROS; DICHO METODO COMPRENDE ADMINISTRAR ORALMENTE UNA COMPOSICION FARMACEUTICA QUE CONTIENE EL COMPUESTO DE FORMULA (I) E HIDROXITOLUENO BUTILADO
PE2012002183A 2010-05-18 2011-05-18 Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos PE20130310A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34591510P 2010-05-18 2010-05-18

Publications (1)

Publication Number Publication Date
PE20130310A1 true PE20130310A1 (es) 2013-04-06

Family

ID=44992319

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012002183A PE20130310A1 (es) 2010-05-18 2011-05-18 Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos

Country Status (9)

Country Link
US (1) US20130331347A1 (es)
AU (1) AU2011255630B2 (es)
BR (1) BR112012029259A8 (es)
CA (1) CA2799386A1 (es)
CL (1) CL2012003201A1 (es)
CO (1) CO6670518A2 (es)
MX (1) MX2012013374A (es)
PE (1) PE20130310A1 (es)
WO (1) WO2011146621A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2826662A1 (en) * 2011-02-04 2012-08-09 Optimer Pharmaceuticals, Inc. Treatment of bacterial infections
RU2015140498A (ru) * 2013-03-08 2017-04-13 Сипла Лимитед Фармацевтические композиции для ректального введения
CN103275152B (zh) * 2013-05-29 2015-11-18 华北制药集团新药研究开发有限责任公司 一种高纯度非达霉素的制备方法
CN103920017B (zh) * 2014-05-09 2016-08-17 马金风 一种治疗宫颈炎的药物组合物
CN104098637B (zh) * 2014-07-09 2017-01-04 浙江海正药业股份有限公司 一种纯化非达霉素的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0511119A (pt) * 2004-05-14 2007-11-27 Optimer Pharmaceuticals Inc tratamento de doenças associadas com o uso de antibióticos
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US20080176927A1 (en) * 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins

Also Published As

Publication number Publication date
CL2012003201A1 (es) 2013-07-05
BR112012029259A8 (pt) 2021-03-23
AU2011255630B2 (en) 2015-04-30
US20130331347A1 (en) 2013-12-12
AU2011255630A1 (en) 2013-01-10
WO2011146621A9 (en) 2012-04-12
MX2012013374A (es) 2013-05-06
CO6670518A2 (es) 2013-05-15
WO2011146621A2 (en) 2011-11-24
BR112012029259A2 (pt) 2021-03-02
CA2799386A1 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
DOP2017000310A (es) Inhibidores de metalo-beta-lactamasa
BR112015029309A2 (pt) derivados de polimixina e seu uso em terapia de combinação junto com antibióticos diferentes
GT201700132A (es) Compuestos de isoxazol de ácido hidroxámico como inhibidores de lpxc
PE20130310A1 (es) Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos
MD4577B1 (ro) Compoziţii masticabile de uz veterinar care conţin agent activ izoxazolinic şi utilizarea acestora în tratamentul sau prevenirea unei infestări sau infecţii parazitare
GT201500088A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
BR112012021086A2 (pt) composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
IN2014CN00568A (es)
EA201201680A1 (ru) Морфолинопиримидины и их применение в терапии
ECSP10010345A (es) Inhibidores de beta-lactamasa
AR108021A1 (es) Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3
EA201390626A1 (ru) Производные гидроксамовой кислоты и применение указанных производных в лечении бактериальных инфекций
ECSP14030572A (es) Formulaciones proliposomales de testosterona
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CR20140086A (es) Tratamientos de combinación para hepatitis c
BR112012021931A2 (pt) composto, composição farmacêutica, método para tratar uma infecção bacteriana, e, uso de composto
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
BR112015006868A2 (pt) composições antibióticas de tazobactam arginina
SV2013004451A (es) Compuestos y su uso
CU20150066A7 (es) Compuestos tricíclicos para inhibir el canal cftr
DOP2019000119A (es) Moduladores de ROR gamma (RORy)
ES2530755T3 (es) Terapia de combinación para el tratamiento del cáncer
WO2014145713A3 (en) Aminoglycoside antibiotics with reduced ototoxicity
NI201200196A (es) Agentes terapéuticos 976
AR105378A1 (es) Métodos de tratamiento de trastornos del desarrollo con gaboxadol

Legal Events

Date Code Title Description
FC Refusal